Project Grant R21AG089491
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$436K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Urbana, IL 61801, USA
Similar Awards
This $622,000 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the role of mitochondrial complex I deficiency in Alzheimer's disease and dementia. The study, conducted by the University of Maryland, Baltimore, will utilize humanized amyloid beta mouse models to determine the effects of complex I deficiency on Alzheimer's proteinopathy and susceptibility to the disease. Key objectives include developing an assay...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $308,000.00 to investigate the mechanisms by which amyloid-beta 42 (Aβ42) interferes with mitochondrial liquid-liquid phase separation in Alzheimer's disease. The two-year project aims to (1) determine the impact of Aβ42 on mitochondrial ribonucleoprotein granule dynamics, and (2) use optogenetic control to modulate Aβ42 and mitochondrial ribonucleoprotein granules in mitochondria. The goal is...
This federal Project Grant award, valued at $131,027.00, was provided by the National Institute on Aging under the Aging Research program (CFDA 93.866) to The Leland Stanford Junior University. The award aims to study neuronal proteostasis, the maintenance of protein health, during brain aging and Alzheimer's disease (AD). The key products and services to be delivered under this grant include: Conducting in vivo experiments using a novel bioorthogonal non-canonical amino acid tagging (BONCAT)...
This federal Project Grant award of $3,579,235 from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to investigate the role of peripheral insulin resistance and inflammation, particularly in the liver, on Alzheimer's disease pathogenesis. The project aims to: 1) Define age-related changes in metabolism and inflammation in peripheral organs and the brain during Alzheimer's-relevant neurodegeneration in a mouse model, and 2) Delineate the liver-brain connection by...
The University of Missouri System was awarded a $392,026 Project Grant from the National Institute on Aging (CFDA 93.866 - Aging Research) to develop an innovative approach for treating Alzheimer's disease (AD). The key product being delivered is a novel therapeutic intervention that aims to systematically and sustainably elevate nicotinamide adenine dinucleotide (NAD+) levels in the body to counteract NAD+ decline associated with AD progression. The project will utilize a helper-dependent...
This $146,922 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to determine the gene expression landscape that distinguishes hippocampal engram cells (neural ensembles representing individual memories) from non-engram cells, and how this landscape changes with age and in an Alzheimer's disease mouse model. The research will use cutting-edge techniques like single-nuclear RNA sequencing and RNA interference to identify key molecular...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), provides $328,000 to an interdisciplinary research team at the University of California, San Francisco (UCSF) to conduct a pilot study titled "Alzheimer's Disease Organelle Proteome Task (ADOPT) - Pilot Phase." The project aims to quantitatively measure the organelle proteome, including protein abundance, post-translational modifications, and protein...
This federal Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) provides $169,560 to the Regents of the University of Michigan to research ways to reverse neural network dysfunction in Alzheimer's disease (AD) and related dementias. The key objectives are to: Identify disrupted gene expression in inhibitory interneurons within the hippocampus and cortex of human AD brains to uncover therapeutic targets for restoring cognitive function....
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the role of the NOX2 enzyme in mediating the brain dysfunction associated with Alzheimer's disease (AD). The $842,175 award, effective December 15, 2024 through November 30, 2029, will allow the J. David Gladstone Institutes, a non-profit biomedical research organization, to explore the potential of a novel NOX2 antagonist (GSK2795039) in mitigating AD-related pathologies such...
The National Institute on Aging awarded Case Western Reserve University $1,785,220 under the Aging Research program (CFDA 93.866) from May 2022 to April 2025. The university will research the role of deubiquitinase USP19 in the pathogenesis of TDP-43, a protein implicated in neurodegenerative diseases like frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Using mouse models, human post-mortem tissues, and molecular and cell biology techniques, the university aims to validate...